MUN:SAZ

Stock Analysis Report

Executive Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide.

Snowflake

Fundamentals

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has STADA Arzneimittel's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.7%

SAZ

0.5%

DE Pharmaceuticals

2.4%

DE Market


1 Year Return

n/a

SAZ

-3.8%

DE Pharmaceuticals

4.9%

DE Market

Return vs Industry: Insufficient data to determine how SAZ performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SAZ performed against the German Market.


Shareholder returns

SAZIndustryMarket
7 Day-1.7%0.5%2.4%
30 Day2.1%-1.1%2.3%
90 Day2.5%8.2%2.7%
1 Yearn/a-0.5%-3.8%8.2%4.9%
3 Yearn/a30.4%15.8%18.3%8.0%
5 Yearn/a30.8%9.1%44.2%24.6%

Price Volatility Vs. Market

How volatile is STADA Arzneimittel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is STADA Arzneimittel undervalued compared to its fair value and its price relative to the market?

19.08x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: SAZ (€85.8) is trading above our estimate of fair value (€72.59)

Significantly Below Fair Value: SAZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SAZ is good value based on its PE Ratio (19.1x) compared to the Pharmaceuticals industry average (22.5x).

PE vs Market: SAZ is good value based on its PE Ratio (19.1x) compared to the German market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SAZ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SAZ is overvalued based on its PB Ratio (4.7x) compared to the DE Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is STADA Arzneimittel forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

1.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SAZ's forecast earnings growth (1.2% per year) is above the savings rate (0.2%).

Earnings vs Market: SAZ's earnings (1.2% per year) are forecast to grow slower than the German market (12.8% per year).

High Growth Earnings: SAZ's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if SAZ's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if SAZ's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SAZ's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has STADA Arzneimittel performed over the past 5 years?

27.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SAZ's earnings have grown significantly by 27% per year over the past 5 years.

Accelerating Growth: SAZ's earnings growth over the past year (74.6%) exceeds its 5-year average (27% per year).

Earnings vs Industry: SAZ earnings growth over the past year (74.6%) exceeded the Pharmaceuticals industry 1.9%.


Return on Equity

High ROE: Whilst SAZ's Return on Equity (22.75%) is high, this metric is skewed due to their high level of debt.


Return on Assets

ROA vs Industry: SAZ has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: SAZ has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is STADA Arzneimittel's financial position?


Financial Position Analysis

Short Term Liabilities: SAZ's short term assets (€1.5B) exceeds its short term liabilities (€1.0B)

Long Term Liabilities: SAZ's short term assets (1.5B) exceeds its long term liabilities (1.4B)


Debt to Equity History and Analysis

Debt Level: SAZ's debt to equity ratio (102.5%) is considered high

Reducing Debt: SAZ's debt to equity ratio has reduced from 153.2% to 102.5% over the past 5 years.

Debt Coverage: SAZ's debt is well covered by operating cash flow (28.5%).

Interest Coverage: SAZ's interest payments on its debt are well covered by EBIT (9.1x coverage).


Balance Sheet

Inventory Level: SAZ has a high level of physical assets or inventory.

Debt Coverage by Assets: SAZ's debt is covered by short term assets (assets are 1.177120x debt).


Next Steps

Dividend

What is STADA Arzneimittel's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SAZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SAZ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SAZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SAZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: SAZ is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SAZ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of STADA Arzneimittel's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Peter Goldschmidt (55yo)

1.1yrs

Tenure

€1,248,000

Compensation

Mr. Peter Goldschmidt serves as the President of Sandoz Inc. Mr. Goldschmidt serves as Head of North American Operations at Sandoz International GmbH and has been its President of Sandoz US since July 2013 ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Peter's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Insufficient data to compare Peter's compensation with company performance.


Management Age and Tenure

2.1yrs

Average Tenure

54.5yo

Average Age

Experienced Management: SAZ's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

2.1yrs

Average Tenure

57yo

Average Age

Experienced Board: SAZ's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mark Keatley (62yo)

    CFO & Member of Executive Board

    • Tenure: 2.1yrs
    • Compensation: €1.24m
  • Peter Goldschmidt (55yo)

    Chairman of the Executive Board & CEO

    • Tenure: 1.1yrs
    • Compensation: €1.25m
  • Miguel Fernandez (54yo)

    CTO & Member of Executive Board

    • Tenure: 1.3yrs
    • Compensation: €704.00k
  • Kay Reubelt

    Director of Investor Relations

    • Tenure: 3.1yrs
  • Sebastian Kramer-Bach (44yo)

    Executive Vice President of Corporate Communication

    • Tenure: 2.8yrs

Board Members

  • Michael Siefke (52yo)

    Member of Supervisory Board

    • Tenure: 2.1yrs
  • Günter von Au (68yo)

    Chairman of Supervisory Board

    • Tenure: 2.1yrs
    • Compensation: €304.02k
  • Thomas Meyer (77yo)

    Chairman of Advisory Board

    • Tenure: 0yrs
  • Wolfgang Berger

    Member of Advisory Board

    • Tenure: 0yrs
  • Frank-R. Leu

    Deputy Chairman of Advisory Board

    • Tenure: 0yrs
  • Rika Aschenbrenner

    Member of Advisory Board

    • Tenure: 0yrs
  • Reimar von Kolczynski

    Member of Advisory Board

    • Tenure: 0yrs
  • Jan-Nicolas Garbe (38yo)

    Member of Supervisory Board

    • Tenure: 2.1yrs
  • Jens Steegers (39yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €193.40k
  • Eric Cornut (62yo)

    Member of Supervisory Board

    • Tenure: 3.8yrs
    • Compensation: €92.41k

Company Information

STADA Arzneimittel Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: STADA Arzneimittel Aktiengesellschaft
  • Ticker: SAZ
  • Exchange: MUN
  • Founded: 1895
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €5.385b
  • Shares outstanding: 62.26m
  • Website: https://www.stada.de

Number of Employees


Location

  • STADA Arzneimittel Aktiengesellschaft
  • Stadastrasse 2-18
  • Bad Vilbel
  • 61118
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STDA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDFeb 1998
0OM4LSE (London Stock Exchange)YesCommon SharesGBEURFeb 1998
SAZMUN (Boerse Muenchen)YesCommon SharesDEEURFeb 1998
SAZSWX (SIX Swiss Exchange)YesCommon SharesCHCHFFeb 1998

Biography

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:50
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.